Items with tag "immunotherapy"

News

Scientists unravel role of glutamine synthetase in the spread of cancer

Scientists have discovered an essential mechanism in the spread of cancer. A team led by professor Massimiliano Mazzone (VIB-KU Leuven) and professor Alessandra Castegna (University of Bari) has d…

Read more

Celyad announces initiation of the SHRINK trial

SHRINK study to evaluate the synergetic effect of the concurrent administration of CYAD-01 (CAR-T NKG2D) with standard chemotherapy in patients suffering from metastatic colorectal cancer.

Read more

argenx receives first preclinical milestone payment in AbbVie collaboration

ARGX-115, an antibody targeting to inhibit the release of TGF-beta from regulatory T-cells in an innovative way, reaches its first preclinical milestone. This triggers a $10 million payment from d…

Read more

Biocartis receives grant for development of a fully automated MSI test

Belgian diagnostics producer receives grant from Flemish government to develop microsatellite instability (MSI) test in collaboration with VIB-KULeuven. Not only will the test offer prognosis esti…

Read more

Celyad obtains FDA approval to initiate the NKR-2 CAR-T cells THINK trial in the USA

Celyad announced that the U.S. FDA authorized the initiation of the THINK trial in the U.S. THINK evaluates NKR-2 CAR-T cells in seven indications, five solid cancers and two hematological maligna…

Read more

Celyad Announces Registration of the first patient in the Belgian THINK trial

Celyad commences THINK trial with its cell-based CAR-T/NKR-2 immunotherapy 

Read more

GiGa gets one step closer to curing atopic dermatitis

Atopic dermatitis (AD) affects up to 20% of children worldwide. It is the most common inflammatory skin disease, characterized by pruritus, eczema and abnormal IgE responses to environmental subst…

Read more

Celyad about to start second cancer immunotherapy clinical trial

Celyad will soon initiate the THINK clinical trial. THINK is the second clinical trial of its NKR-2 product candidate, a CAR-T cell therapy using NKG2D ligands as a target, to evaluate safety and …

Read more

First human treated with CRISPR

Back in October, CRISPR was applied for the first time in the treatment of a human being. The patient was being treated for an aggressive form of lung cancer. In a form of immunotherapy, patient i…

Read more

WHITE PAPER ON CANCER IMMUNOTHERAPY - CALL OPEN

BioVox is currently developing a White Paper on Cancer Immunotherapy, showcasing innovators and world leaders in this exciting field. Are you an innovative player and do you want to promote y…

Read more

Celyad cuts deal with Ono Pharmaceutical on immunotherapy treatment

Japan's Ono Pharmaceutical will license a cancer treatment of Celyad. The collaboration is very welcome, as two weeks ago, the Walloon company had to share disappointing results of C-Cure, a stem …

Read more

Insights

Fresh insights into the future of cell therapy

Fresh insights into the future of cell therapy

The first edition of Science for health was held in the heart of Brussels on September 11 with a focus on cell therapy. The event attracted over 300 researchers, clinicians and industry profession…

Read more

Living on the edge: the challenge of doing things differently in cell therapy

Living on the edge: the challenge of doing things differently in cell therapy

Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science for health event in September the visionary Christia…

Read more

Damya Laoui at the forefront of cancer immunotherapy

Damya Laoui at the forefront of cancer immunotherapy

Photo copyright: VUB / Thierry Geenen Last year, Damya Laoui received the prestigious American MIT-prize for young innovators under 35 for her research on cancer immunotherapy.  She is current…

Read more

Curing hay fever - ASIT Biotech allergy vaccines

Curing hay fever - ASIT Biotech allergy vaccines

The sun is shining, the grass is green, but hay fever season is at its peak! Many people (myself included) will spend a lot of money on antihistamines and tissues this summer. Wouldn’t it be lovel…

Read more

Celyad: CAR-T cells with natural killer skills fight cancer

Celyad: CAR-T cells with natural killer skills fight cancer

Celyad, based in Mont-Saint-Guibert (Belgium), was originally established in 2004 as a company active in regenerative cell therapy. However, two years ago, Celyad decided to move into immuno-oncol…

Read more

Vaccinating against cancer with dendritic cells

Vaccinating against cancer with dendritic cells

Founded as a spin-off from the French Blood Bank, PDC*line Pharma is focused on developing immunotherapeutic vaccines. These vaccines contain their proprietary and unique plasmacytoid dendritic ce…

Read more

ImmunXperts: your partner for in vitro assays in cancer immunotherapy

ImmunXperts: your partner for in vitro assays in cancer immunotherapy

Although immunotherapy in cancer is booming, it isn’t by any measure an easy field to navigate. Many oncology ventures willing to explore this new terrain find themselves quickly lost in an array …

Read more

Very promising cancer treatment: RNAi immunotherapy

Very promising cancer treatment: RNAi immunotherapy

RXi Pharmaceuticals was co-founded by Craig Mello, PhD, the co-recipient of the 2006 Nobel Prize in Medicine for the discovery of RNA interference (RNAi). To advance the use of RNAi into therapeut…

Read more

IDO 1: a promising new target for immunotherapy

IDO 1: a promising new target for immunotherapy

iTeos Therapeutics started in 2012 as a spin-off from the Ludwig Institute for Cancer Research (LICR), one of the top three cancer institutes in the world, and the UCL. In 2014, they licensed righ…

Read more

Immunotherapy: a paradigm shift in cancer treatment

Immunotherapy: a paradigm shift in cancer treatment

An excerpt from the BioVox White paper on Cancer Immunotherapy.

Read more

CAR-T: The T-cell training program to fight cancer

CAR-T: The T-cell training program to fight cancer

Immunotherapy is by far the hottest topic in the cancer research world. One immune approach in particular has created high expectations: CAR-T. This method of reprogramming T-cells has shown impre…

Read more

All in on cancer immunotherapy

All in on cancer immunotherapy

Founded in 2011, iTeos Therapeutics began its activities at the end of 2012. Active in the field of cancer immunotherapy, the company develops innovative drugs by focusing on the tumor microenviro…

Read more

Engineered immune cells to fight cancer

Engineered immune cells to fight cancer

Our own immune T-cells can be one of the best defense lines against cancer. Walloon biopharmaceutical company Celyad is using an innovative approach to harness a patient's own immune system to dir…

Read more

Cancer immunotherapy: the ultimate ally in the tumor war

Cancer immunotherapy: the ultimate ally in the tumor war

Can immunotherapy cure cancer? Fighting cancer with our own immune system. It sounds promising. At the end of the 1800s, the controversial Dr. William Coley  suggested that infections fuel the imm…

Read more

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

XpandInnovation UGent Itera Life Science GSK V-Bio Ventures KU Leuven Biowin Turnstone Flanders.bio Janssen

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.